Sickle Cell Comorbidities Increase Risk for Worse COVID Outc
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Patients with sickle cell disease (SCD) who have a history of disease-related comorbidities were found to be at greater risk for worse COVID-19 outcomes, researchers reported.

Patients with sickle cell disease (SCD) are at high risk of developing serious infections, therefore, understanding the impact that severe acute respiratory syndrome coronavirus 2 infection has on this population is important. This study sought to identify factors associated with hospitalization and serious COVID-19 illness in children and adults with SCD. They established the international SECURE-SCD Registry to collect data on patients with SCD and COVID-19 illness.

They used multivariable logistic models to estimate the independent effects of age, sex, genotype, hydroxyurea, and SCD-related and -nonrelated comorbidities on hospitalization, serious COVID-19 illness, and pain as a presenting symptom during COVID-19 illness. 750 COVID-19 illness cases in patients with SCD were reported to the registry. Researchers identified history of pain and SCD heart/lung comorbidities as risk factors for hospitalization in children.

History of pain was also a risk factor for hospitalization in adults. Children with history of pain, SCD heart/lung comorbidities, and SCD renal comorbidities and adults with history of pain were at higher risk of developing serious COVID-19 illness.

History of pain and SCD renal comorbidities also increased risk of pain during COVID-19 in children; history of pain, SCD heart/lung comorbidities, and female sex increased risk of pain during COVID-19 in adults. Hydroxyurea showed no effect on hospitalization and COVID-19 severity, but it lowered the risk of presenting with pain in adults during COVID-19.